Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Authors

Nicholas Viney

Published

September 22, 2016

Abstract

Supporters

Support the authors with ResearchCoin

Journal

The Lancet

Topics

DOI

10.1016/s0140-6736(16)31009-1

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Authors

Nicholas Viney

Published

September 22, 2016

Abstract

Supporters

Support the authors with ResearchCoin

Journal

The Lancet

Topics

DOI

10.1016/s0140-6736(16)31009-1

Paper

Paper

Paper

Paper

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Abstract

Supporters

Journal

Topics

DOI

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Abstract

Supporters

Journal

Topics

DOI